Dashboard
Manage Tickers

MAIA MAIA Biotechnology, Inc.

NYSE MAIABiotech.com


$ 1.25 $ 0.00 (0 %)    

Monday, 03-Nov-2025 07:31:10 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.22 $ 0.00 (0 %)
DIA $ 475.88 $ 0.00 (0 %)
SPY $ 684.14 $ 0.00 (0 %)
TLT $ 89.76 $ 0.00 (0 %)
GLD $ 369.10 $ 0.00 (0 %)
$ 1.24
$ 1.34
$ 1.25 x 2,350
$ 1.38 x 1
-- - --
$ 1.22 - $ 3.48
504,107
na
40.91M
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-21-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-22-2022 06-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

maia-biotechnology-presents-trial-in-progress-poster-at-2025-aacr-nci-eortc-conference-co-enrolls-five-patients-from-taiwan-and-turkey-in-expansion-phase-of-thio-101-phase-2-trial
MAIA Biotechnology Presents Trial In Progr...
10/27/2025 14:54:11

maia-biotechnology-reports-efficacy-of-ateganosine-in-high-risk-non-small-cell-lung-cancer-at-esmo-2025
MAIA Biotechnology Reports Efficacy Of Ate...
10/23/2025 12:38:22

Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWS...

maia-biotechnology-announces-736600-private-placement-of-603769-shares-at-122share
MAIA Biotechnology Announces $736,600 Priv...
10/13/2025 20:21:01

maia-biotechnology-authorizes-up-to-90-of-liquid-assets-in-bitcoin-ethereum-and-usd-coin-for-new-digital-treasury-strategy
MAIA Biotechnology Authorizes Up To 90% Of...
10/07/2025 12:49:28

MAIA's Board of Directors authorizes holdings of up to 90% of the Company's liquid assets in cryptocurrencies (BTC), Et...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 21:06:15

maia-biotechnology-announces-225m-private-placement-of-1733766-shares-at-purchase-price-of-130share
MAIA Biotechnology Announces $2.25M Privat...
09/29/2025 20:30:48

maia-biotechnology-receives-23m-nih-grant-to-expand-thio-101-phase-2-trial-for-advanced-lung-cancer-in-us
MAIA Biotechnology Receives $2.3M NIH Gran...
09/24/2025 12:04:14

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advance...

maia-biotechnology-highlights-efficacy-data-from-phase-2-clinical-trial-thio-101-evaluating-ateganosine-sequenced-with-immune-cpi-cemiplimab-in-patients-with-advanced-nsclc
MAIA Biotechnology Highlights Efficacy Dat...
09/11/2025 13:29:49

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focuse...

maia-biotechnology-to-present-phase-2-thio--cemiplimab-data-in-ici-resistant-ansclc-at-iaslc-wclc-2025-poster-highlights-pfs-improvement
MAIA Biotechnology To Present Phase 2 THIO...
09/05/2025 13:05:05

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC)CHICAGO, Sept. 05, ...

maia-biotechnologys-phase-2-thio-101-trial-developments-published-in-cells-journal
MAIA Biotechnology's Phase 2 THIO-101 Tria...
08/27/2025 13:07:47

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focuse...

maia-biotechnology-granted-european-patent-titled-mercaptopurine-ribonucleoside-analogues-for-altering-telomerase-mediated-telomere
MAIA Biotechnology Granted European Patent...
08/13/2025 13:04:42

maia-biotechnology-q2-eps-018-beats-024-estimate
MAIA Biotechnology Q2 EPS $(0.18) Beats $(...
08/11/2025 13:48:23

MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0....

maia-biotechnology-announces-fda-fast-track-for-first-in-class-telomere-targeting-drug-in-nsclc-latest-data-in-pivotal-phase-2-thio-101-clinical-trial-shows-median-overall-survival-of-178-months
MAIA Biotechnology Announces FDA Fast Trac...
07/28/2025 12:05:58

Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment marketLatest data in pi...

maia-biotechnology-publishes-preclinical-data-from-second-generation-ateganosine-prodrugs-platform-in-nucleic-acids-research-titled-novel-telomere-targeting-dual-pharmacophore-dinucleotide-prodrugs-for-anticancer-therapy
MAIA Biotechnology Publishes Preclinical D...
07/17/2025 13:21:02

Manuscript featured in leading open-access peer-reviewed scientific journal Nucleic Acids Research

maia-biotechnology-doses-first-patient-in-taiwan-in-expansion-phase-of-thio-101-phase-2-trial-for-advanced-non-small-cell-lung-cancer
MAIA Biotechnology Doses First Patient In ...
07/09/2025 13:16:16

MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies...

maia-biotechnology-to-present-data-highlighting-cancer-telomere-targeting-agent-and-next-generation-treatments-at-febs-2025
MAIA Biotechnology To Present Data Highlig...
07/01/2025 13:17:05

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focuse...

maia-biotechnology-enters-into-clinical-master-supply-agreement-with-roche-for-future-studies-investigating-combination-of-maias-thio-sequenced-with-roches-cpi-atezolizumab-for-cancer-treatments
MAIA Biotechnology Enters Into Clinical Ma...
06/18/2025 13:17:19

Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer...

maia-biotechnologys-experimental-cancer-drug-shows-tripled-survival-vs-standard-chemotherapy-in-pretreated-lung-cancer-patients
MAIA Biotechnology's Experimental Cancer D...
06/05/2025 18:28:49

MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and im...

maia-biotechnology-says-new-partial-response-identified-in-patient-after-20-months-of-treatment-in-phase-2-thio-101-clinical-trial-evaluating-ateganosine-sequenced-with-regenerons-immune-cpi-libtayo-in-nsclc-patients
MAIA Biotechnology Says New Partial Respon...
06/05/2025 15:13:00

MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focuse...

maia-biotechnology-reports-updated-phase-2-thio-101-trial-data-showing-median-overall-survival-of-178-months-with-ateganosine-plus-cemiplimab-in-heavily-pre-treated-nsclc-patients
MAIA Biotechnology Reports Updated Phase 2...
06/05/2025 12:14:05

Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest dataMAIA Biotechnology, Inc. (N...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION